• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bedrocan Cannabis appoints three as independent directors

Bedrocan Cannabis appoints three as independent directors

August 21, 2014
CenterWatch Staff

Bedrocan Cannabis, previously Bedrocan Canada has appointed three independent members to its board of directors, enhancing executive oversight and strengthening the health care experience of the company, a licensed researcher and producer of medicinal cannabis in Canada.

Bedrocan's new independent directors are Barry Fishman, former CEO of Teva Canada; Allan Mandelzys, former CEO and senior executive of publicly-traded biotechnology companies; and Roderick Budd, former life sciences practice leader at Ernst & Young. The new appointees join existing Bedrocan directors Marc Wayne, president and CEO of Bedrocan, and chairman Murray Goldman, the founder and chairman of the Goldman Group.

Fishman has agreed to chair the compensation committee of Bedrocan's board. Previously, as CEO of Taro Canada, a specialty pharmaceutical company, Fishman tripled sales, strengthened talent and improved profitability. Prior to Taro, Fishman spent 17 years with Eli Lilly Canada, where he advanced through several cross-functional leadership roles, including vice president of marketing.

Budd has agreed to chair the audit committee of Bedrocan's board. Budd has over 36 years of experience in public accounting serving emerging and growth companies with a focus on those in the life sciences sector.

Mandelzys is an accomplished biotechnology executive with twenty years of experience, most recently as CEO of a clinical stage, publicly-traded pharmaceutical company. Mandelzys is a business development professional with more than fifteen years of successfully leading negotiations and executing strategic partnerships, which include product in-licensing and out-licensing agreements, merger and acquisition transactions, research alliances and master service agreements.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing